This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Solaro, R. J. Search for Related Content PubMed PubMed Citation Articles by Solaro, R. J. Related Collections Animal models of human disease Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Other Vascular biology

(Circulation Research. 2000;87:173.)
© 2000 American Heart Association, Inc.

Editorials

Myosin Light Chain Phosphatase

A Cinderella of Cellular Signaling

R. John Solaro

From the Program in Cardiovascular Sciences, Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, Ill.

Correspondence to R. John Solaro, PhD, Department of Physiology and Biophysics (M/C 901), College of Medicine, University of Illinois at Chicago, 835 S Wolcott Ave, Chicago, IL 60612-7342.

Key Words: small G proteins • myosin light chain • phosphatase • vasospasm • stroke

	Introduction

 
Although several myofilament proteins are modified by protein phosphorylation, the 18-kDa myosin light chain 2 (MLC2) has special significance. In striated muscle, after some experimental struggles, MLC2 phosphorylation was shown to modulate myofilament activation by Ca²⁺.¹ However, in the case of smooth muscle, phosphorylation of the MLC2 by a Ca²⁺ calmodulin–dependent kinase triggers contraction.² The state of MLC2 phosphorylation in smooth muscle determines whether crossbridges are turned off, cycling, or in a latch or catch-like state. Understandably, the initial focus of experiments was on Ca²⁺ and the regulation of MLC2 kinase (MLCK) activity. It was always understood that control of the level of MLC phosphorylation requires some balance of activities and separation of powers between an MLCK and MLC2 phosphatase (MLCP),³ yet little attention was given to the possibility that the activity of MLCP could be modulated. Now MLCP seems to be the Cinderella of phosphoryl group transfer enzymes.

This mindset concerning regulation of MLC2 phosphorylation changed dramatically with two observations. One was evidence that addition of GTP--S to permeable preparations of smooth muscle was able to sensitize the myofilaments to Ca²⁺ and slow down relaxation, alterations suggesting modulation of MLCP.⁴ A second was the elucidation of the functional domains of MLCP,⁵ which consist of a 37-kDa catalytic subunit, a 20-kDa subunit of unknown function, and a 110- to 130-kDa subunit that targets MLCP to myosin. This targeting domain of MLCP, which is termed myosin binding site (MBS) or myosin phosphatase targeting peptide, binds to myosin or MLC2 . . . [Full Text of this Article]

This article has been cited by other articles:

				J. Riise, C. H.T. Nguyen, E. Qvigstad, D. L. Sandnes, J.-B. Osnes, T. Skomedal, F. O. Levy, and K. A. Krobert Prostanoid F receptors elicit an inotropic effect in rat left ventricle by enhancing myosin light chain phosphorylation Cardiovasc Res, December 1, 2008; 80(3): 407 - 415. [Abstract] [Full Text] [PDF]

				J. A. Madden, M. W. Dantuma, E. A. Sorokina, D. Weihrauch, and J. G. Kleinman Telokin expression and the effect of hypoxia on its phosphorylation status in smooth muscle cells from small and large pulmonary arteries Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1166 - L1173. [Abstract] [Full Text] [PDF]

				S. Chrissobolis and C. G. Sobey Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease Stroke, August 1, 2006; 37(8): 2174 - 2180. [Abstract] [Full Text] [PDF]

				R. H. P. Hilgers and R. C. Webb Molecular Aspects of Arterial Smooth Muscle Contraction: Focus on Rho Experimental Biology and Medicine, December 1, 2005; 230(11): 829 - 835. [Abstract] [Full Text] [PDF]

				L. Hazelton and C. Hickey Cinderology: the Cinderella of academic medicine Can. Med. Assoc. J., December 7, 2004; 171(12): 1495 - 1496. [Full Text] [PDF]

				D. L. Lee, R. C. Webb, and L. Jin Hypertension and RhoA/Rho-Kinase Signaling in the Vasculature: Highlights From the Recent Literature Hypertension, December 1, 2004; 44(6): 796 - 799. [Abstract] [Full Text] [PDF]

				R. C. Webb SMOOTH MUSCLE CONTRACTION AND RELAXATION Advan Physiol Educ, December 1, 2003; 27(4): 201 - 206. [Abstract] [Full Text] [PDF]

				N. Bannert, K. Vollhardt, B. Asomuddinov, M. Haag, H. Konig, S. Norley, and R. Kurth PDZ Domain-mediated Interaction of Interleukin-16 Precursor Proteins with Myosin Phosphatase Targeting Subunits J. Biol. Chem., October 24, 2003; 278(43): 42190 - 42199. [Abstract] [Full Text] [PDF]

				A. V. Somlyo New Roads Leading to Ca2+ Sensitization Circ. Res., July 26, 2002; 91(2): 83 - 84. [Full Text] [PDF]

				F. V. Brozovich Myosin Light Chain Phosphatase: It Gets Around Circ. Res., March 22, 2002; 90(5): 500 - 502. [Full Text] [PDF]

				A. N Carr, R. L Sutliff, C. S Weber, P. B Allen, P. Greengard, P. de Lanerolle, E. G Kranias, and R. J Paul Is myosin phosphatase regulated in vivo by inhibitor-1? Evidence from inhibitor-1 knockout mice J. Physiol., July 15, 2001; 534(2): 357 - 366. [Abstract] [Full Text] [PDF]

				C. T. Richards, O. Ogut, and F. V. Brozovich Agonist-induced Force Enhancement. THE ROLE OF ISOFORMS AND PHOSPHORYLATION OF THE MYOSIN-TARGETING SUBUNIT OF MYOSIN LIGHT CHAIN PHOSPHATASE J. Biol. Chem., February 1, 2002; 277(6): 4422 - 4427. [Abstract] [Full Text] [PDF]